Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting No phase listed Observational

IMPACT-Ready Study

ClinicalTrials.gov ID: NCT07931690

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07931690. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Aligning Research to Impact Autism (ARIA) Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT)-Ready Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The IMPACT-Ready Study is a multi-site, international short-term prospective natural history study to develop new outcome measures, clinical endpoints, and biomarkers for autism and related neurodevelopmental conditions. The primary objective is to systematically document over time the behavioral, medical, neurophysiological, and genetic presentation of children with profound autism and related neurodevelopmental conditions. Participants will be initially separated into two cohorts: those with a confirmed diagnosis of a monogenic disorder associated with profound autism, including ARID1B, GRIN2B, RNU4-2, SCN2A, SLC6A1, or other genes of interest (Cohort 1), or those with likely profound or profound autism without a definitive genetic cause for their autism at the time of enrollment who use few or no words to communicate, with significant cognitive impairments (Cohort 2). All participants will complete a baseline visit, and a subset of participants will complete either 6-month or annual follow-up visits based on the results of their genetic testing and their age. After whole genome sequencing and Fragile X testing at the baseline visit, Cohort 2 will be split into 2 groups: Cohort 2a (those with a definitive genetic cause for autism not identified) and Cohort 2b (those with the presence of pathogenic or likely pathogenic variant(s) in a neurodevelopmental gene other than one of the targeted genes of interest AND those that do not meet the criteria for profound/likely profound autism following baseline assessment).

Study identification

NCT ID
NCT07931690
Recruitment status
Not yet recruiting
Study type
Observational
Phase
Not listed
Enrollment
1,250 participants

Conditions and interventions

Eligibility (public fields only)

Age range
0 Years to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2026 (Estimated)
Primary completion
Nov 2033 (Estimated)
Completion
Nov 2040 (Estimated)
Last update posted
Nov 12, 2026

2026 – 2040

United States locations

U.S. sites
10
U.S. states
10
U.S. cities
10
Facility City State ZIP Site status
Children's Hospital Los Angeles/University of California Los Angeles Los Angeles California 90027 —
University of Colorado Anschutz Medical Campus/Children's Hospital of Colorado Aurora Colorado 80045 —
Emory University/Georgia State University/Children's Healthcare of Atlanta Atlanta Georgia 30322 —
Boston Children's Hospital Boston Massachusetts 02115 —
New York State Psychiatric Institute/Weill Cornell Medicine/Columbia University Medical Center Weill Cornell Medicine New York New York 10032 —
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599 —
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229 —
Children's Hospital of Philadelphia/University of Pennsylvania Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104 —
Baylor College of Medicine/Texas Children's Hospital Houston Texas 77030 —
Seattle Children's Hospital/University of Washington Seattle Washington 98105 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07931690, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 12, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.